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Abstract
Background: Leptin plays an important role in energy
homeostasis. There is polymorphism on the leptin
(LEP) gene. Our aim was to compare the tetranucleo-
tide repeat (TTTC)n polymorphism in the 39-flanking
region in the LEP gene on DNA samples from patients
with pre-eclampsia (PE), hemolysis, elevated liver
enzymes, and low platelet (HELLP) syndrome and
healthy pregnant controls.
Methods: Blood samples were collected from healthy
pregnant women (ns88), patients with PE (ns79) and
HELLP (ns77) syndrome. Fluorescent PCR and DNA
fragment analysis was performed from the isolated
DNA for the detection of (TTTC) repeats. The electro-
phoretograms were evaluated and patients were
assigned to two groups; class I low (-190 bp) or class
II high (G190 bp) PCR fragments.
Results: We observed similar distributions of the class
I and class II (TTTC) alleles in the groups studied
(class I allele: healthy pregnant 58.5%; severe pre-
eclamptic 58.3%; HELLP syndrome 52.6%). We detect-
ed a higher frequency of the II/II genotype in HELLP
syndrome patients (32.4%) compared to healthy con-
trols (22.7%). However, the difference was not statis-
tically significant.
Conclusions: In an ethnically homogenous popula-
tion, the LEP gene (TTTC) microsatellite polymor-
phism in the 39-flanking region does not show a
significant difference in the allele and genotype dis-
tribution in healthy pregnant, pre-eclamptic and
HELLP syndrome patients. Furthermore, we recom-
mend a new classification of the class I and class II
alleles based on the distribution of the (TTTC)
microsatellites.
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Introduction
Leptin (LEP) is a 167-amino acid polypeptide hormone
produced in adipose tissue (1, 2). It is secreted into
the bloodstream where it circulates bound to other
proteins. LEP stimulates or inhibits the production of
different neurotransmitters in the brain (3). It is
involved in the regulation of energy homeostasis, in
the neuroendocrine system and in the reproductive
system (4). The expression and secretion of LEP is
correlated with body fat content and adipocyte size
(5). Elevated LEP concentrations have been found in
obese patients (6).
The human LEP gene was assigned to 7q31.3 and
consists of three exons and two introns ;20 kb in
length which encode 3.5 kb of mRNA (1, 7, 8).
LEP plays an important role not only in energy
homeostasis, but also in reproduction. It serves as a
permissive regulator of reproductive maturity (9–15).
LEP also plays a role in the regulation of fetal growth
and development (11, 12, 16). An interesting obser-
vation is that the placenta and ovaries produce LEP,
which then enters the maternal circulation (2, 16).
There is further evidence that it stimulates blood ves-
sel formation (1). Also, LEP is reported to enhance
vascular endothelial growth factor (VEGF) synthesis in
cultured human cytotrophoblast cells (11).
Serum LEP concentrations are higher during preg-
nancy and peaks in the second trimester (15, 17–19).
Shintani et al. (19) identified a highly variable tetra-
nucleotide repeat (TTTC)n on the LEP 39-flanking
region. Muy-Rivera et al. (8) characterized the poly-
morphic alleles by size distribution, short repeats
(class I allele) and long repeats (class II allele). They
classified the alleles into two groups, -160 pb and
)160 pb, based on TTTC repeat units. They found cor-
relation between the occurrence of pre-eclampsia (PE)
and the presence of the I/II genotype. Contradictions
exist among the results of studies on the LEP micro-
satellite in terms of size and the occurrence of dis-
ease. Polymorphic variations of the gene have an
effect on obesity, but it is not clear whether it has an
impact on the development of cardiovascular disease
(20).
PE is a pregnancy-associated syndrome which is a
major cause of maternal and perinatal mortality and
morbidity. There is a severe form of PE with hemol-
ysis, elevated liver enzymes and low platelets, termed
hemolysis, elevated liver enzymes, and low platelet
(HELLP) syndrome. Several studies have shown over
expression of LEP on microarray experiments in PE
(21, 22). We decided to determine the LEP tetra-
nucleotide repeat polymorphism in healthy, pre-
eclamptic, and HELLP syndrome patients.
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Table 1 Clinical characteristic of the study patients.
Controls Pre-eclampsia HELLP Level of
ns88 ns79 ns77 significance (p)
Average age, years 28.1 29.0 28.5 NS
Primipara 42 (47.7%) 38 (48.1%) 41 (53.2%) NS
Systolic blood pressure 110 (105–120) 170 (140–220) 160 (130–220) -0.01
Diastolic blood pressure 70 (60–80) 104 (100–115) 102 (90–140) -0.01
Gestational age at 40 (39–40) 32 (25–39) 32 (23–39) -0.05
delivery, weeks
Mann-Whitney U-test was performed. HELLP, hemolysis, elevated liver enzymes, and low platelet.
Materials and methods
Patients
Healthy pregnant controls (ns88), patients with severe PE
(ns79) and HELLP syndrome (ns77), at the 1st Department
of Obstetrics and Gynecology of Semmelweis University
were asked to participate in the study. Table 1 shows the
primary demographic parameters of the patients. Control
patients were consecutively selected from a group of nor-
motensive, healthy pregnant women who were undergoing
routine blood tests, and were excluded if they developed
hypertensive disorder. Severe PE was defined as new-onset
persistent hypertension (G160/110 mm Hg) and new-onset
proteinuria (G1000 mg/24 h) following the 20th gestational
week, in the absence of urinary tract infection (23).
In HELLP syndrome cases the following criteria were
defined: hemolysis, classified by increased lactate dehydro-
genase activity ()600 IU/L); elevated activity of liver
enzymes including increased aspartate aminotransferase
and alanine aminotransferase ()70 IU/L); and thrombocy-
topenia (F100 platelets =109/L). The Ethical Committee of
the Semmelweis University approved the study. All partici-
pants were informed and agreed to their involvement in the
study.
DNA isolation
Three mL of peripheral blood was collected from each
patient into an ethylenediaminetetraacetic acid (EDTA) tube.
Genomic DNA was extracted from 0.2 mL of samples using
the High Pure PCR Template Isolation kit (Roche, Mannheim,
Germany), according to the manufacturer’s instructions (24).
Determination of the (TTTC)n polymorphism
Fluorescent PCR and DNA fragment analyses was performed
using the 59-6-FAM-AGT TCA AAT AGA GGT CCA AAT CA-
39 forward and 59-TTC TGA GGT TGT GTC ACT GGC A-39
reverse primer sequences (8). The PCR mix contained 25 mL
of the Qiagen Multiplex PCR mix (Qiagen, Hilden, Germany)
and 0.3 mM of primers in a final 50 mL volume. PCR was
performed for 32 cycles of 15 s at 958C, 15 s at 558C and 20 s
at 728C, with an initial denaturation of 10 min at 958C and a
final extension of 10 min at 728C. Four mL of the PCR prod-
ucts were added to 19 mL of formamid and 1 mL of GeneScan
500-ROX Size Standard (PE Applied Biosystems, Foster City,
CA, USA). The mixture was denatured at 958C for 3 min and
cooled to 48C for 5 min. Electrophoresis was performed
using an ABI 3130 Genetic Analyzer with POP7 gel (PE
Applied Biosystems). The results were analyzed with Gene-
scan Analysis software (PE Applied Biosystems) (25).
Statistical analyses of the data
Statistical analyses were performed with the STATISTICA
software package (version 8; StatSoft, Inc, Tulsa, OK, USA).
The statistical significance of the differences between patient
groups was evaluated using the Mann-Whitney non-para-
metric U-test. A p-0.05 was considered to be statistically
significant.
Pearson Chi-square (x2) test was used for comparing
groups of categorical data of allele and genotype frequen-
cies. The observed allele and genotype frequencies of the
LEP receptor small tandem repeats (STRs) were tested for
Hardy-Weinberg equilibrium.
Results
We established a fluorescent PCR and DNA fragment
analysis method for the determination of the LEP
gene (TTTC)n microsatellite polymorphism. The cap-
illary electrophoresis system allows the assignment
of the fragment size with 1 bp size precision. The
alleles were assigned into two groups based on the
size distribution of the (TTTC)n tetranucleotide
repeats. Shorter repeats (-190 bp) were classified as
class I, and longer repeats as class II alleles (G190 bp)
(19, 26).
Table 2 shows the allele size distribution in the
healthy controls, pre-eclamptic and HELLP syndrome
patients. We observed a lower frequency of class I
alleles in HELLP syndrome patients; 52.6% compared
to 58.5% in healthy controls and 58.3% in PE. These
differences were not statistically significant.
Table 3 shows the genotype distribution of the LEP
gene in healthy controls, PE and HELLP syndrome
patients. The occurrence of the II/II genotype in the PE
(20.3%) and HELLP (32.4%) syndrome patients was
compared to healthy controls (22.7%) using statistical
analysis. These results did not show a significant dif-
ference among the groups studied.
Figure 1 shows the electrophoretogram of a sample
with genotype I/II, where the representative short and
longer alleles were observed.
Figure 2 shows the allele distribution of the (TTTC)
microsatellites. There are two exact groups of alleles
in each group of patients.
The Hardy-Weinberg equilibrium was calculated
using the Hardy-Weinberg equilibrium calculator
(www.changbioscience.com/genetics/hardy.html). The
rule was not valid for the patient population studied.
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Table 2 Leptin (TTTC)n tetranucleotid allele distribution in healthy pregnant, severe pre-eclamptic and HELLP syndrome
patients.
Subjects (TTTC)n allele Level of
Class I Class II
significance (p)
Healthy pregnant (ns88) 103 (58.5%) 73 (41.5%) 0.9564a
Severe pre-eclamptic (ns79) 92 (58.3%) 66 (41.7%) 0.3174b
HELLP syndrome (ns77) 81 (52.6%) 73 (47.4%) 0.2796a
Pearson x2-test was performed. aHealthy pregnant controls compared to severe pre-eclamptic or HELLP syndrome patients.
bSevere pre-eclamptic compared to HELLP. HELLP, hemolysis, elevated liver enzymes, and low platelet.
Table 3 Leptin (TTTC)n tetranucleotid genotype distribution in healthy pregnant, severe pre-eclamptic and HELLP syndrome
patients.
Subjects Genotype I/I Genotype I/II Genotype II/II Level of
significance (p)
Healthy controls (ns88) 35 (39.8%) 33 (37.5%) 20 (22.7%) 0.7639a
Severe pre-eclamptic (ns79) 29 (36.7%) 34 (43.0%) 16 (20.3%) 0.227b
HELLP syndrome (ns77) 28 (36.4%) 25 (31.2%) 24 (32.4%) 0.468a
Pearson x2-test was performed. aHealthy pregnant compared to severe pre-eclamptic or HELLP syndrome patients. bSevere
pre-eclamptic compared to HELLP. HELLP, hemolysis, elevated liver enzymes, and low platelet.
Figure 1 Electrophoretogram showing the detection of
leptin (TTTC)n polymorphism.
PCR fragments with low molecular weight (class I) and high
molecular weight (class II) alleles are shown on the Figure,
representing a I//II genotype sample.
Figure 2 Leptin (TTTC)n allele distribution in the samples
studied.
Figure showing the leptin (TTTC)n allele distribution in the
samples studied. The cut-off at 190 bp is clearly visible.
Discussion
We determined LEP (TTTC)n polymorphism in healthy
pregnant controls, pre-eclamptic and HELLP syn-
drome patients. We did not find any differences in the
distribution of the (TTTC) microsatellite repeats
among the different study groups. However, the fre-
quency of the allele class II and the genotype II/II were
higher in HELLP syndrome patients.
We classified the alleles based on their molecular
weight. Class I had the PCR fragment size -190, while
class II had G190 bp. The fluorescent PCR and DNA
fragment analysis makes determination of the LEP
(TTTC)n polymorphism fast and reliable.
Muy-Rivera et al. (8) studied 40 pre-eclamptic and
39 controls and detected higher frequencies of geno-
type I/II in PE. They did not find any II/II genotype in
their DNA samples from pre-eclamptic patients. There
are several differences between our study and the
above-mentioned American study. One of the differ-
ences was that our study involved an ethnically
homogeneous population, Caucasian Hungarians,
and we had a higher number of cases with PE. Based
on a search of the literature, our study is the first per-
formed on the (TTTC)n tetranucleotide polymorphism
in patients with HELLP syndrome. Muy-Rivera et al.
(8) discussed discrepancies and inconsistent result in
previous publications (19, 27). Porreca et al. (20) stud-
ied the relationship between the LEP microsatellite
polymorphism and the risk of cardiovascular disease,
but they did not find any correlation. They concluded
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that LEP microsatellite polymorphism does not
appear to have an effect on plasma LEP concentra-
tions, body mass index (BMI), or hypertension. We
assume ethnic differences in the frequency of the LEP
gene (TTTC) microsatellite length should be evident,
and it could cause the discrepancies observed in the
different groups.
We suggest reclassification of the allele classes
used by Muy-Rivera et al. (8). The distribution of the
microsatellites shows two peaks. There is a loop from
180 bp to 210 bp. Thus, the two groups are separated
better using the new classification with the limit at
190 bp. There should be a consensus for the new clas-
sification of I and class II alleles.
Masuzaki et al. did not find any correlation between
plasma LEP concentrations and BMI in pregnant
women (2). On the contrary, Considine et al. found
significant correlation between normal-weight and
obese individuals (28). Our department serves as a
regional center for high-risk pregnancies. Since our
patients receive infusion therapy and other treat-
ments upon arrival to our department, determination
of LEP concentrations is not reliable. We are not able
to compare our genotypes with the LEP concentration
measurements in the population studied.
Some authors have hypothesized and suggested
that hyperleptinemia results from insulin resistance
(29), tissue hypoxemia (30) or chronic systemic
inflammation (31). Numerous authors found higher
concentration of LEP in pre-eclamptic pregnancies
and a linear relationship between the severity of PE
and LEP concentrations (32). It is suspected that this
increase may be caused by hypoxia. Lu et al. showed
increased serum LEP concentrations and slight
decreases in LEP receptor concentrations (33). They
interpreted this as due to greater bioavailability of LEP
in PE. Muy-Riviera et al. stated that regardless of the
mechanisms of the function of LEP, it is a potential
marker for risk of PE (8).
Irrespective of the contradictions in the effect of LEP
(TTTC)n polymorphism on different diseases, it
remains an exciting target for research. We did not
find a difference in the allele and genotype distribu-
tion in PE and HELLP syndrome compared to healthy
pregnant individuals. It seems to not play a role in the
development of this disease. We recommend using a
new classification of the two allele subgroups based
on their distribution. This may help solve the discrep-
ancies seen in previous studies.
Conflict of interest statement
None of the author has any financial or other conflict of inter-
ests. None has been or is presently employed or supported
by any company.
Acknowledgements
The study was supported by the FP6, ‘‘Pregenesys – 037244’’
grant.
References
1. Henson MC, Castracane VD. Leptin in pregnancy. Biol
Reprod 2000;63:1219–28.
2. Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shi-
gemoto M, et al. Human obese gene expression. Adi-
pocyte-specific expression and regional differences in
the adipose tissue. Diabetes 1995;44:855–8.
3. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and
obesity: a huge review. Am J Epidemiol 2005;162:
101–14.
4. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT,
Rabinowitz D, et al. Weight-reducing effects of the plas-
ma protein encoded by the obese gene. Science 1995;
269:543–6.
5. Houseknecht KL, Baile CA, Matteri RL, Suprlock ME. The
biology of leptin: a review. J Anim Sci 1998;76:405–20.
6. Caro JF, Sinha MK, Kolazynski JW, Zhang PL, Considine
RV. Leptin: the tale of an obesity gene. Diabetes 1996;
45:1455–62.
7. Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki
T, et al. Structural organization and chromosomal
assignment of the human obese gene. J Biol Chem 1995;
270:27728–33.
8. Muy-Rivera M, Ning Y, Frederic IO, Vadachkoria S, Luthy
DA, Williams MA. Leptin, soluble leptin receptor and lep-
tin gene polymorphism in relation to preeclampsia risk.
Physiol Res 2005;54:167–74.
9. Cunningham MJ, Clifton DK, Steiner RA. Leptin’s action
on the reproductive axis: perspectives and mechanisms.
Biol Reprod 1999;60:216–22.
10. Clarke IJ, Henry BA. Leptin and reproduction. Rev
Reprod 1999;4:48–55.
11. Islami D, Bischof P, Chardonnens D. Modulation of pla-
cental vascular endothelial growth factor by leptin and
hCG. Mol Hum Reprod 2003;9:395–8.
12. Kiess W, Siebler T, Englaro P, Kratzsch J, Deutscher J,
Meyer K, et al. Leptin as a metabolic regulator during
fetal and neonatal life and in childhood and adolescence.
J Pediatr Clin Endocrinol Metab 1998;11:483–96.
13. Foster DL, Nagatani S. Physiological perspectives on lep-
tin as a regulator of reproduction: role in timing of
puberty. Biol Reprod 1999;60:205–15.
14. Kiess W, Reich A, Meyer K, Glasow A, Deutscher J,
Klammt J, et al. A role for leptin in sexual maturation
and puberty? Horm Res 1999;51(Suppl 3):55–63.
15. Helland IB, Reseland JE, Saugstad OD, Drevon CA. Lep-
tin levels in pregnant women and newborn infants: gen-
der differences and reduction during the neonatal
period. Pediatrics 1998;101:E12.
16. Hassink SG, de Lancey E, Sheslow DV, Smith-Kirwin SM,
O’Connor DM, Considine RV, et al. Placental leptin: an
important new growth factor in intrauterine and neona-
tal development? Pediatrics 1997;100:E1.
17. Hardie L, Trayhurn P, Abramovich D, Fowler P. Circulat-
ing leptin in women: a longitudional study in the men-
strual cycle and during pregnancy. Clin Endocrinol 1997;
47:101–6.
18. Highman TJ, Friedman JE, Huston LP, Wong WW, Cata-
lano PM. Longitudional changes in maternal serum lep-
tin concentrations, body composition, and resting meta-
bolic rate in pregnancy. Am J Obstet Gynecol 1998;178:
1010–5.
19. Shintani M, Ikegami H, Yamato E, Kawaguchi Y, Fujisa-
wa T, Nakagawa Y, et al. A novel microsatellite poly-
morphism in the human OB gene: a highly polymorphic
marker for linkage analysis. Diabetologia 1996;39:1398–
401.
20. Porreca E, Di Febbo C, Pintor S, Baccante G, Gatta V,
Moretta V, et al. Microsatellite polymorphism of the
Nagy et al.: Leptin gene microsatellite polymorphism 1037
Article in press - uncorrected proof
human leptin gene (LEP) and risk of cardiovascular dis-
ease. Int J Obes (Lond) 2006;30:209–13.
21. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi
H, Udagawa Y. Microarray analysis of differentially
expressed genes in placental tissue derived from early
and late onset severe pre-eclampsia. Placenta 2007;28:
487–97.
22. Sitras V, Paulssen RH, Grønaas H, Leirvik J, Hanssen TA,
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